Summit Therapeutics Inc. Long-Lived Assets
Summit Therapeutics Inc. (SMMT) had Long-Lived Assets of $8.24 million as of 2024-09-30, per its 10-Q filed 2024-10-30.
Financial Statements › Notes › Segment Reporting
us-gaap:NoncurrentAssets · last filed 2024-10-30
- 2024-09-30: Long-Lived Assets $8.24M.
- 2024-06-30: Long-Lived Assets $8.94M.
- 2024-03-31: Long-Lived Assets $9.55M.
- 2023-12-31: Long-Lived Assets $6.06M.
| Period end | Long-Lived Assets |
|---|---|
| 2024-09-30 | $8.24M 10-Q · filed 2024-10-30 |
| 2024-06-30 | $8.94M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $9.55M 10-Q · filed 2024-05-01 |
| 2023-12-31 | $6.06M 10-Q · filed 2024-10-30 |
| 2023-09-30 | $6.63M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $7.22M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $4.34M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $5.08M 10-K · filed 2024-02-20 |
| 2022-09-30 | $5.16M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $3.11M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $3.40M 10-Q · filed 2022-05-11 |
| 2021-12-31 | $3.48M 10-K · filed 2023-03-09 |
| 2020-12-31 | $1.28M 10-K/A · filed 2022-12-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |